A Phase 1 interventional study of MK-8808 and MabThera® (rituximab) in Rheumatoid Arthritis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-07-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 40th largest by enrollment, is one of 4 that started in 2011, is one of 6 in phase 1, and was the 34th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
30 studies in Arthritis, Rheumatoid by Merck & Co., Inc: 2 open now, 3 under way, none of them phase 3. Of 25 finished, 18 (72%) have results posted.
Among the 30 studies in Arthritis, Rheumatoid by Merck & Co., Inc, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2011, is one of 3 in phase 1, and was the 25th registered.
Merck & Co., Inc’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 30 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This is a study of the overall safety, tolerability, and pharmacokinetics (PK) of MK-8808 versus rituximab (MabThera® and Rituxan®) in participants with moderate to severe RA with an inadequate response or intolerance to methotrexate.
In Part A of the base study, participants are randomized to either MK-8808 or MabThera®. In Part B of the base study, participants are randomized to either MK-8808, MabThera®, or Rituxan®. Participants enrolled in Part A are not eligible to participate in Part B. In both Parts A and B, participants will receive one or two courses of therapy, with each course including two infusions of the study drugs.
The extension portion of the study (Part C) will sequentially follow the base study beginning at Week 52 and continue for an additional 54 weeks. All participants who meet eligibility criteria and continue into the study extension will be treated with open-label MK-8808. Participants randomized to MK-8808 in the base study will remain on the same therapy. Participants randomized to rituximab (MabThera® or Rituxan®) in the base study will be switched to MK-8808 for the extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the Treatment Period, participants receive one course of MK-8808 (500 mg/m\^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period. During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period. Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated.
Biological: MK-8808 · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Loratadine
During the Treatment Period, participants receive one course of MabThera® (500 mg/m\^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period. During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period. Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated.
Biological: MK-8808 · Biological: MabThera® (rituximab) · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Loratadine
In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period. In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period. Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated.
Biological: MK-8808 · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Loratadine
In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period. In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period. Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated.
Biological: MK-8808 · Biological: MabThera® (rituximab) · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Loratadine
In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period. In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period. Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated.
Biological: MK-8808 · Drug: Methotrexate · Biological: Rituxan® (rituximab) · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Loratadine
MK-8808 500 mg/m\^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
MabThera® 500 mg/m\^2 or 1000 mg administered by IV on Day 1 and Day 15
Also known as: Rituxan®, Rituximab
Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
Also known as: Trexall®, Rheumatrex®
Rituxan® 1000 mg administered by IV on Day 1 and Day 15
Also known as: Rituximab
Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Also known as: Paracetamol
Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Also known as: Claritin®
Part A: Area Under the Concentration-time Curve From Day 0 to Day 84 (AUC0-84day) After a Single Course of Treatment
AUC is a measure of the amount of drug in the plasma over time; samples are collected at intervals from pre-dose up to 84 days after the dose. Descriptive data values and associated dispersion measures (confidence intervals) are expressed in terms of the factor 10E6.
Time frame: Day 1 (pre- and post-dose), Day 3, Day 5, Day 8, Day 15, Day 17, Day 19, Day 22, Day 29, Day 43, Day 57, Day 85
Part B: Area Under the Concentration-time Curve From Day 0 to Day 84 (AUC0-84day) After a Single Course of Treatment
AUC is a measure of the amount of drug in the plasma over time; samples are collected at intervals from pre-dose up to 84 days after the dose.
Time frame: Day 1 (pre- and post-dose), Day 3, Day 5, Day 8, Day 15, Day 17, Day 19, Day 22, Day 29, Day 43, Day 57, Day 85
Number of Participants Who Experienced at Least One Adverse Event
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
Time frame: Parts A and B: Up to 52 weeks; Extension A and B: Up to 106 weeks
Number of Participants Who Discontinued Study Drug Due to Adverse Events
Discontinuation/withdrawal of study treatment due to an adverse event was performed at the discretion of the investigator or the Sponsor for safety concerns. An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
Time frame: Parts A and B: Up to Week 28; Extension A and B: Up to 82 weeks
Number of Participants With Immunoglobulin G (IgG) Response in the Extension Study
Serum IgG levels are determined over course of therapy with MK-8808 in the Extension Study.
Time frame: Week 54, Week 68, Week 80, Week 94, Week 106
Number of Participants Positive for Anti-Drug Antibody (ADA) Formation in the Extension Study
Serum ADA positivity is determined over course of therapy with MK-8808 in the Extension Study.
Time frame: Week 54, Week 56, Week 68, Week 80, Week 82, Week 94, Week 106
Part A: Maximum Concentration (Cmax) After the Second Infusion of a Single Course of Treatment
Cmax is a measure of the maximum plasma concentration of drug; samples are collected on Day 15 after the second infusion of the first course of treatment. Descriptive data values and associated dispersion measures (confidence intervals) are expressed in terms of the factor 10E3.
Time frame: Day 15
Part B: Cmax After the Second Infusion of a Single Course of Treatment
Cmax is a measure of the maximum plasma concentration of drug; samples are collected on Day 15 after the second infusion of the first course of treatment.
Time frame: Day 15
Part A: Number of ACR20, ACR50, and ACR70 Responders at Week 24
American College of Rheumatology (ACR) Responder Index is based on a set of evaluations: the Investigator Tender Joint Count/Number of Tender Joints (out of 68 Joints); Investigator Swollen Joint Count/Number of Swollen Joints (out of 66 Joints); Patient Global Assessment of Disease Activity (PGAD); Investigator Global Assessment of Disease Activity (IGAD); Patient Global Assessment of Pain (PGAP); Health Assessment Questionnaire Disability Index (HAQ-DI); and ESR. ACR response indicates percent change (ie, improvement) from baseline (20%, 50%, 70%) PGAD \& IGAD: assessment of function on a 4-point Likert scale: 0=very well to 3=unable to do PGAP: pain due to arthritis measured on a 0-100 mm visual analog scale: Left hand marker-"no pain"; right hand marker-"extreme pain" HAQ-DI: assessment of 8 daily living activities (dress/groom; arise; eat; walk; reach; grip; hygiene; common daily activities) on 4-point Likert scale: 0=no difficulty to 3=unable to do
Time frame: Week 24
Part B: Number of ACR20, ACR50, and ACR70 Responders at Week 24
American College of Rheumatology (ACR) Responder Index is based on a set of evaluations: the Investigator Tender Joint Count/Number of Tender Joints (out of 68 Joints); Investigator Swollen Joint Count/Number of Swollen Joints (out of 66 Joints); Patient Global Assessment of Disease Activity (PGAD); Investigator Global Assessment of Disease Activity (IGAD); Patient Global Assessment of Pain (PGAP); Health Assessment Questionnaire Disability Index (HAQ-DI); and ESR. ACR response indicates percent change (ie, improvement) from baseline (20%, 50%, 70%) PGAD \& IGAD: assessment of function on a 4-point Likert scale: 0=very well to 3=unable to do PGAP: pain due to arthritis measured on a 0-100 mm visual analog scale: Left hand marker-"no pain"; right hand marker-"extreme pain" HAQ-DI: assessment of 8 daily living activities (dress/groom; arise; eat; walk; reach; grip; hygiene; common daily activities) on 4-point Likert scale: 0=no difficulty to 3=unable to do
Time frame: Week 24
Change From Baseline in Disease Activity in 28 Joints C-Reactive Protein Score (DAS28-CRP) by Time-point
The DAS28-CRP is a combination scoring method for function using the European League against Rheumatism (EULAR) 28 joint count and the CRP value. The DAS28-CRP scores range from 2.0 to 10.0 with higher values indicating a higher disease activity. A DAS28-CRP below the score of 2.6 is interpreted as Remission. CRP values below lower limit of quantification (LLQ) (\<0.4 mg/dL) were set to 0.2 mg/dL in the calculation of DAS28-CRP.
Time frame: Baseline, Week 6, Week 12
The study enrolled participants 18 to 65 years of age with a diagnosis of moderate/severe rheumatoid arthritis (RA), naive to treatment or having failed \>=1 anti-TNF agent, and on a stable dose of methotrexate. Not all participants completing the Treatment Period entered the Extension Period due to study early termination.
| Milestone | Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg | Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg | Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg | Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg | Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg |
|---|---|---|---|---|---|
| Started | 23 | 22 | 18 | 19 | 18 |
| Completed | 22 | 21 | 8 | 6 | 7 |
| Not completed | 1 | 1 | 10 | 13 | 11 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Unknown due to early stopping of study | 0 | 0 | 8 | 11 | 7 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg | Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg | Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg | Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg | Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg |
|---|---|---|---|---|---|
| Started | 15 | 13 | 1 | 1 | 3 |
| Completed | 12 | 12 | 1 | 0 | 3 |
| Not completed | 3 | 1 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 3 | 1 | 0 | 1 | 0 |
AUC is a measure of the amount of drug in the plasma over time; samples are collected at intervals from pre-dose up to 84 days after the dose. Descriptive data values and associated dispersion measures (confidence intervals) are expressed in terms of the factor 10E6.
| hr*mg/mL | Part A: MK-8808 500 mg/m^2 | Part A: MabThera® 500 mg/m^2 |
|---|---|---|
| Part A: Area Under the Concentration-time Curve From Day 0 to Day 84 (AUC0-84day) After a Single Course of Treatment | 110.56 (94.51 to 129.32) | 110.12 (91.97 to 131.84) |
AUC is a measure of the amount of drug in the plasma over time; samples are collected at intervals from pre-dose up to 84 days after the dose.
No measurements were reported for this outcome.
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
| Participants | Part A: MK-8808 500 mg/m^2 | Part A: MabThera 500 mg/m^2 | Part B: MK-8808 1000 mg | Part B: MabThera 1000 mg | Part B: Rituxan 1000 mg | Extension A: MK-8808 500 mg/m^2 /MK-8808 1000 mg | Extension A: MabThera 500 mg/m^2 /MK-8808 1000 mg | Extension B: MK-8808 1000 mg /MK-8808 1000 mg | Extension B: MabThera 1000 mg /MK-8808 1000 mg | Extension B: Rituxan1000 mg/MK-8808 1000 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event | 18 | 21 | 12 | 16 | 13 | 2 | 2 | 0 | 0 | 0 |
Discontinuation/withdrawal of study treatment due to an adverse event was performed at the discretion of the investigator or the Sponsor for safety concerns. An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
| Participants | Part A: MK-8808 500 mg/m^2 | Part A: MabThera® 500 mg/m^2 | Part B: MK-8808 1000 mg | Part B: MabThera® 1000 mg | Part B: Rituxan® 1000 mg | Extension A: MK-8808 500 mg/m^2 /MK-8808 1000 mg | Extension A: MabThera® 500 mg/m^2 /MK-8808 1000 mg | Extension B: MK-8808 1000 mg /MK-8808 1000 mg | Extension B: MabThera® 1000 mg /MK-8808 1000 mg | Extension B: Rituxan® 1000 mg/MK-8808 1000 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to Adverse Events | 2 | 2 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
Cmax is a measure of the maximum plasma concentration of drug; samples are collected on Day 15 after the second infusion of the first course of treatment. Descriptive data values and associated dispersion measures (confidence intervals) are expressed in terms of the factor 10E3.
| ng/mL | Part A: MK-8808 500 mg/m^2 | Part A: MabThera® 500 mg/m^2 |
|---|---|---|
| Part A: Maximum Concentration (Cmax) After the Second Infusion of a Single Course of Treatment | 326.49 (287.72 to 370.49) | 332.39 (287.48 to 384.31) |
Cmax is a measure of the maximum plasma concentration of drug; samples are collected on Day 15 after the second infusion of the first course of treatment.
No measurements were reported for this outcome.
American College of Rheumatology (ACR) Responder Index is based on a set of evaluations: the Investigator Tender Joint Count/Number of Tender Joints (out of 68 Joints); Investigator Swollen Joint Count/Number of Swollen Joints (out of 66 Joints); Patient Global Assessment of Disease Activity (PGAD); Investigator Global Assessment of Disease Activity (IGAD); Patient Global Assessment of Pain (PGAP); Health Assessment Questionnaire Disability Index (HAQ-DI); and ESR. ACR response indicates percent change (ie, improvement) from baseline (20%, 50%, 70%) PGAD \& IGAD: assessment of function on a 4-point Likert scale: 0=very well to 3=unable to do PGAP: pain due to arthritis measured on a 0-100 mm visual analog scale: Left hand marker-"no pain"; right hand marker-"extreme pain" HAQ-DI: assessment of 8 daily living activities (dress/groom; arise; eat; walk; reach; grip; hygiene; common daily activities) on 4-point Likert scale: 0=no difficulty to 3=unable to do
| Participants | Part A: MK-8808 500 mg/m^2 | Part A: MabThera® 500 mg/m^2 |
|---|---|---|
| ACR20 | 23 | 20 |
| ACR50 | 16 | 15 |
| ACR70 | 4 | 4 |
American College of Rheumatology (ACR) Responder Index is based on a set of evaluations: the Investigator Tender Joint Count/Number of Tender Joints (out of 68 Joints); Investigator Swollen Joint Count/Number of Swollen Joints (out of 66 Joints); Patient Global Assessment of Disease Activity (PGAD); Investigator Global Assessment of Disease Activity (IGAD); Patient Global Assessment of Pain (PGAP); Health Assessment Questionnaire Disability Index (HAQ-DI); and ESR. ACR response indicates percent change (ie, improvement) from baseline (20%, 50%, 70%) PGAD \& IGAD: assessment of function on a 4-point Likert scale: 0=very well to 3=unable to do PGAP: pain due to arthritis measured on a 0-100 mm visual analog scale: Left hand marker-"no pain"; right hand marker-"extreme pain" HAQ-DI: assessment of 8 daily living activities (dress/groom; arise; eat; walk; reach; grip; hygiene; common daily activities) on 4-point Likert scale: 0=no difficulty to 3=unable to do
| Participants | Part B: MK-8808 1000 mg | Part B: MabThera® 1000 mg | Part B: Rituxan® 1000 mg |
|---|---|---|---|
| ACR20 | 16 | 17 | 15 |
| ACR50 | 12 | 12 | 13 |
| ACR70 | 2 | 1 | 1 |
The DAS28-CRP is a combination scoring method for function using the European League against Rheumatism (EULAR) 28 joint count and the CRP value. The DAS28-CRP scores range from 2.0 to 10.0 with higher values indicating a higher disease activity. A DAS28-CRP below the score of 2.6 is interpreted as Remission. CRP values below lower limit of quantification (LLQ) (\<0.4 mg/dL) were set to 0.2 mg/dL in the calculation of DAS28-CRP.
| Score | Part A: MK-8808 500 mg/m^2 | Part A: MabThera® 500 mg/m^2 |
|---|---|---|
| Week 6 (n=22, n=20) | -1.39 ± 1.02 | -1.16 ± 1.26 |
| Week 12 (n=21, n=21) | -1.68 ± 1.12 | -2.04 ± 1.39 |
Serum IgG levels are determined over course of therapy with MK-8808 in the Extension Study.
No measurements were reported for this outcome.
Serum ADA positivity is determined over course of therapy with MK-8808 in the Extension Study.
No measurements were reported for this outcome.
Collected over Parts A and B: Up to 52 weeks; Extension A and B: Up to 106 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: MK-8808 500 mg/m^2 | — | 1/23 (4.3%) | 15/23 (65.2%) |
| Part A: MabThera 500 mg/m^2 | — | 1/22 (4.5%) | 17/22 (77.3%) |
| Part B: MK-8808 1000 mg | — | 2/18 (11.1%) | 11/18 (61.1%) |
| Part B: MabThera 1000 mg | — | 0/19 (0%) | 16/19 (84.2%) |
| Part B: Rituxan 1000 mg | — | 0/18 (0%) | 13/18 (72.2%) |
| Extension A: MK-8808 500 mg/m^2 /MK-8808 1000 mg | — | 0/15 (0%) | 2/15 (13.3%) |
| Extension A: MabThera® 500 mg/m^2 /MK-8808 1000 mg | — | 0/13 (0%) | 2/13 (15.4%) |
| Extension B: MK-8808 1000 mg /MK-8808 1000 mg | — | 0/1 (0%) | 0/1 (0%) |
| Extension B: MabThera® 1000 mg /MK-8808 1000 mg | — | 0/1 (0%) | 0/1 (0%) |
| Extension B: Rituxan® 1000 mg/MK-8808 1000 mg | — | 0/3 (0%) | 0/3 (0%) |
| Event | Part A: MK-8808 500 mg/m^2 | Part A: MabThera 500 mg/m^2 | Part B: MK-8808 1000 mg | Part B: MabThera 1000 mg | Part B: Rituxan 1000 mg | Extension A: MK-8808 500 mg/m^2 /MK-8808 1000 mg | Extension A: MabThera® 500 mg/m^2 /MK-8808 1000 mg | Extension B: MK-8808 1000 mg /MK-8808 1000 mg | Extension B: MabThera® 1000 mg /MK-8808 1000 mg | Extension B: Rituxan® 1000 mg/MK-8808 1000 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 0/23 | 0/22 | 1/18 | 0/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/23 | 0/22 | 1/18 | 0/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 0/23 | 1/22 | 0/18 | 0/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| PneumoniaInfections and infestations | 1/23 | 0/22 | 0/18 | 0/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| Event | Part A: MK-8808 500 mg/m^2 | Part A: MabThera 500 mg/m^2 | Part B: MK-8808 1000 mg | Part B: MabThera 1000 mg | Part B: Rituxan 1000 mg | Extension A: MK-8808 500 mg/m^2 /MK-8808 1000 mg | Extension A: MabThera® 500 mg/m^2 /MK-8808 1000 mg | Extension B: MK-8808 1000 mg /MK-8808 1000 mg | Extension B: MabThera® 1000 mg /MK-8808 1000 mg | Extension B: Rituxan® 1000 mg/MK-8808 1000 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Throat irritationRespiratory, thoracic and mediastinal disorders | 3/23 | 1/22 | 0/18 | 4/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| InfluenzaInfections and infestations | 0/23 | 3/22 | 2/18 | 1/19 | 0/18 | 1/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/23 | 3/22 | 0/18 | 0/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| Hepatitis CInfections and infestations | 3/23 | 1/22 | 0/18 | 0/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| Infusion related reactionInjury, poisoning and procedural complications | 3/23 | 2/22 | 0/18 | 0/19 | 1/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| HeadacheNervous system disorders | 3/23 | 2/22 | 1/18 | 0/19 | 1/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| BronchitisInfections and infestations | 0/23 | 1/22 | 2/18 | 1/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| NasopharyngitisInfections and infestations | 1/23 | 0/22 | 0/18 | 1/19 | 2/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| Respiratory tract infectionInfections and infestations | 1/23 | 1/22 | 0/18 | 0/19 | 2/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| HypersensitivityImmune system disorders | 0/23 | 1/22 | 0/18 | 2/19 | 0/18 | 0/15 | 0/13 | 0/1 | 0/1 | 0/3 |
| Age, Continuous(years) | Part A: MK-8808 500 mg/m^2 | Part A: MabThera® 500 mg/m^2 | Part B: MK-8808 1000 mg | Part B: MabThera® 1000 mg | Part B: Rituxan® 1000 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 51.7 ± 6.7 | 51.5 ± 8.4 | 46.4 ± 10.9 | 48.7 ± 12.4 | 46.2 ± 10.5 | 49.1 ± 9.9 |
| Sex: Female, Male(Participants) | Part A: MK-8808 500 mg/m^2 | Part A: MabThera® 500 mg/m^2 | Part B: MK-8808 1000 mg | Part B: MabThera® 1000 mg | Part B: Rituxan® 1000 mg | Total |
|---|---|---|---|---|---|---|
| Female | 20 | 19 | 14 | 16 | 15 | 84 |
| Male | 3 | 3 | 4 | 3 | 3 | 16 |
No study locations are listed for this record.
The record gives a start of Jul 2011, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab